Evolent Announces Third Quarter 2026 Results

Evolent’s Q3 2026 revenue rose 51% year over year to $725.4 million, while net loss narrowed to $23.6 million from $26.9 million. Adjusted EBITDA fell to $34.3 million from $39.0 million and its margin declined to 4.7% from 8.1%; the company raised its 2026 Adjusted EBITDA guidance to $130–$135 million and reiterated revenue guidance of $2.6–$2.7 billion. It also reported a four-year renewal and two expansions or new agreements, including oncology coverage across additional states.

Analysis

The key issue is unit economics, not reported growth: the Performance Suite’s higher revenue and PMPM coincide with a materially higher medical expense ratio, while adjusted EBITDA declined and margin compressed. That combination is consistent with growth carrying more claims exposure or a less favorable mix; it does not yet demonstrate operating leverage. The 2026 EBITDA raise is constructive, but the full-year range implies a meaningful Q4 step-up from the year-to-date run rate. The call should clarify whether this depends on claims seasonality, contract mix, or execution gains—and how much of the 93% MER is economically borne by Evolent.

Cash generation also deserves a quality discount: receivables rose, and the claims/performance reserve increase was a major operating cash-flow offset. With substantial debt and planned capex, weak collections or reserve normalization could constrain deleveraging even if adjusted EBITDA meets guidance. The new oncology scope offers a 2027 growth catalyst, but a January launch creates implementation and ramp risk; management’s AI-margin-expansion claim has no quantified evidence here. Payers’ affordability needs support demand, while internal alternatives at large insurers and competing care-management vendors limit pricing power.

Near term, guidance may support sentiment, but the margin/claims questions could dominate the call. Over 1–3 months, monitor quarterly MER, cash conversion, and Q4 delivery. Over 6–18 months, successful oncology launches and stable claims economics could improve operating leverage; persistently elevated MER would undermine that thesis. Contrarian angle: headline revenue growth and contract wins may overstate progress if incremental business is lower-margin or risk-bearing.

Key Decisions for Investors

• Keep EVH as a cautious/underweight rather than chase the growth headline. Reassess after the call: require management to explain claims economics and the Q4 EBITDA bridge before adding.
• Watch for a conditional short/relative underweight if management cannot show a credible path to lower or stable MER and Q4 EBITDA delivery; the thesis is falsified by improving MER, stronger cash conversion, and guidance delivery without further margin erosion.
• Treat the January 2027 oncology expansion as a catalyst to monitor, not a near-term earnings upgrade: verify implementation costs, go-live timing, and early member adoption before underwriting material margin expansion.
• Track accounts-receivable collections, claims reserves, and debt reduction alongside adjusted EBITDA. Deteriorating cash conversion or failure to make stated debt-reduction progress would weaken the equity case even if non-GAAP earnings meet guidance.